We are live on ! Find out more
MIM

MetLife Investment Management Portfolio holdings

AUM $19.6B
1-Year Est. Return 32.64%
This Fund
S&P 500
This Quarter Est. Return
+9.69%
1 Year Est. Return
+32.64%
3 Year Est. Return
+107.14%
5 Year Est. Return
+140.16%
10 Year Est. Return
AUM
$13.7B
AUM Growth
-$178M
Cap. Flow
-$1.14B
Cap. Flow %
-8.27%
Top 10 Hldgs %
25.57%
Holding
3,040
New
254
Increased
776
Reduced
1,044
Closed
100

Sector Composition

Rank Sector Weight
1 Technology 26.03%
2 Healthcare 12.56%
3 Financials 11.14%
4 Consumer Discretionary 11.02%
5 Industrials 9.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MACK
2851
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$69K ﹤0.01%
+5,610
New +$70.2K
CIFR icon
2852
Cipher Digital
CIFR
$7.42B
$68.9K ﹤0.01%
+24,087
New +$59.3K
SPB icon
2853
Spectrum Brands
SPB
$2.03B
$68.2K ﹤0.01%
874
-30
-3% -$2.14K
WTM icon
2854
White Mountains Insurance
WTM
$5.06B
$68.1K ﹤0.01%
49
-3
-6% -$4.22K
CUE icon
2855
Cue Biopharma
CUE
$128M
$67.6K ﹤0.01%
+617
New +$72.5K
CRGE
2856
DELISTED
Charge Enterprises, Inc. Common Stock
CRGE
$67.6K ﹤0.01%
68,934
DNA icon
2857
Ginkgo Bioworks
DNA
$486M
$67.4K ﹤0.01%
905
+287
+46% +$17K
PIII icon
2858
P3 Health Partners
PIII
$38.9M
$67.1K ﹤0.01%
+449
New +$62.1K
SKYT
2859
DELISTED
SkyWater Technology
SKYT
$66.9K ﹤0.01%
7,107
PAG icon
2860
Penske Automotive Group
PAG
$14.3B
$66.3K ﹤0.01%
398
-136
-25% -$19.7K
KLXE icon
2861
KLX Energy Services
KLXE
$35.1M
$66.1K ﹤0.01%
+6,792
New +$66.9K
AFRM icon
2862
Affirm
AFRM
$24.6B
$66K ﹤0.01%
4,308
-273
-6% -$3.62K
BTAI icon
2863
BioXcel Therapeutics
BTAI
$32.7M
$65.6K ﹤0.01%
616
LBPH
2864
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$65.6K ﹤0.01%
+8,932
New +$67.6K
LE icon
2865
Lands' End
LE
$391M
$65.5K ﹤0.01%
8,441
VOR icon
2866
Vor Biopharma
VOR
$1.32B
$65.5K ﹤0.01%
+1,060
New +$96.8K
PINC
2867
DELISTED
Premier
PINC
$64.9K ﹤0.01%
2,348
-90
-4% -$2.57K
PLX icon
2868
Protalix BioTherapeutics
PLX
$211M
$64.7K ﹤0.01%
+32,363
New +$77.1K
VRCA icon
2869
Verrica Pharmaceuticals
VRCA
$87.4M
$64.6K ﹤0.01%
+1,119
New +$67.9K
KRMD icon
2870
KORU Medical Systems
KRMD
$152M
$64.5K ﹤0.01%
+18,708
New +$73.4K
CACC icon
2871
Credit Acceptance
CACC
$5.99B
$64.5K ﹤0.01%
127
-37
-23% -$17.3K
PSTX
2872
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$63.9K ﹤0.01%
+36,309
New +$92.7K
NVCT icon
2873
Nuvectis Pharma
NVCT
$637M
$63.4K ﹤0.01%
+3,970
New +$63.4K
FEAM icon
2874
5E Advanced Materials
FEAM
$73.1M
$63.1K ﹤0.01%
836
AGO icon
2875
Assured Guaranty
AGO
$3.29B
$62.8K ﹤0.01%
1,125
-67
-6% -$3.56K

Similar funds

MetLife Investment Management's Q2 2023 Portfolio in Review

As of Q2 2023, MetLife Investment Management held 3,040 positions worth $13.7B, down 1.3% from $13.9B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

MetLife Investment Management withdrew a net $1.14B in Q2 2023, closing 100 positions and reducing 1,044 holdings. Its most notable exit was Evoqua Water Technologies Corp. Common Stock, an estimated $3.05M position sold in full.

By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 22% a quarter earlier, followed by Healthcare and Financials.

Against the trend, MetLife Investment Management opened a new position in Knife River worth $2.46M.

  • MetLife Investment Management's largest Q2 2023 buy was Knife River: 56,478 shares worth $2.46M.
  • MetLife Investment Management added most to Meta Platforms (Facebook) in Q2 2023, an estimated $14.9M increase.
  • MetLife Investment Management's biggest Q2 2023 reduction was iShares iBoxx $ Investment Grade Corporate Bond ETF, cutting an estimated $901M.
  • MetLife Investment Management fully exited Evoqua Water Technologies Corp. Common Stock in Q2 2023, selling an estimated $3.05M.
  • MetLife Investment Management's ten largest holdings make up 26% of its $13.7B portfolio in Q2 2023.
  • MetLife Investment Management opened 254 new positions and closed 100 in Q2 2023.
  • MetLife Investment Management's portfolio value fell 1.3% quarter-over-quarter to $13.7B.

Based on MetLife Investment Management's 13F filing for Q2 2023, filed 10 Aug 2023.